Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 15 obese men (BMI\>30), aged 18 to 55, with glomerular hyperfiltration (creatinine clearance\>130 ml/min)) and 10 normal body weight men (BMI\<25), aged 18 to 55.~Exclusion Criteria:~* Heart failure, CKD, COPD~* Known allergy to furosemide, acetazolamide, inulin or amino-hippurate~* Pharmacologic treatment for hypertension, cardiac disease, diabetes mellitus~* Treatment with corticosteroids, antiepileptics or NSAID

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Furosemide first, then Acetazolamide (Type: EXPERIMENTAL): Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
- Acetazolamide first, then Furosemide (Type: EXPERIMENTAL): Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.

Based on this trial design, predict the completion outcome and termination type (if applicable).